greeksoup/ stock research
Stock research / United States / Funds / Venrock Adviser, LLC

Venrock Adviser, LLC

CIK 1615982 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Venrock Adviser, LLC reported 33 US-listed holdings worth $3.30 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Apogee Therapeutics Inc. (34.2%), Oruka Therapeutics Inc. (12.0%) and Erasca Inc. (9.9%). Against the quarter before, it opened 4 positions, added to 5, trimmed 5 and sold out of 4.

Filed before as VR Adviser, LLC.

Reported holdings$3.30B+23.1% on Q1 2026
Positions33as many as Q1 2026
The largest ten80.4%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
Added toHeldTrimmed
APGE34.2%ORKA12.0%ERAS9.9%SYRE8.0%DNTH3.5%OCUL3.1%DMRA2.8%SVRA2.8%JBIO2.2%COGT1.9%VRDN1.8%VOR1.7%DYN1.5%MAZE1.4%19 more13.2%

The 14 largest of its 33 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q3 2024: $1.91 billion in 38 positions$1.91BQ3 24Q4 2024: $1.46 billion in 37 positions$1.46BQ4 24Q1 2025: $1.18 billion in 37 positions$1.18BQ1 25Q2 2025: $1.33 billion in 31 positions$1.33BQ2 25Q3 2025: $1.78 billion in 33 positions$1.78BQ3 25Q4 2025: $2.02 billion in 27 positions$2.02BQ4 25Q1 2026: $2.68 billion in 33 positions$2.68BQ1 26Q2 2026: $3.30 billion in 33 positions$3.30BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 4Added 5Held 19Trimmed 5Sold out 4
Opened: 4Added: 5Held: 19Trimmed: 5Sold out: 4

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 4

  1. Achieve Life Sciences Inc. ACHV$18.0 million
  2. Parabilis Medicines Inc. Com PBLS$17.1 million
  3. Research Alliance Corp Iii Ord Shs Cl A RACC$3.2 million
  4. Inmed Pharmaceuticals Inc. INM$50,662

Added to 5

  1. Erasca Inc. ERAS+1.5 million shares · +9%
  2. Relmada Therapeutics Inc. RLMD+2.0 million shares · +41%
  3. X4 Pharmaceuticals Inc. XFOR+1.6 million shares · +485%
  4. Savara Inc. SVRA+1.0 million shares · +7%
  5. Artiva Biotherapeutics Inc. ARTV+434,027 shares · +27%

Trimmed 5

  1. Spyre Therapeutics Inc. SYRE-700,000 shares · -19%
  2. Enliven Therapeutics Inc. ELVN-1.2 million shares · -70%
  3. Cytomx Therapeutics Inc. CTMX-5.0 million shares · -50%
  4. Cogent Biosciences Inc. COGT-357,834 shares · -18%
  5. Viridian Therapeutics Inc. VRDN-624,792 shares · -16%

Sold out of 4

  1. Kalvista Pharmaceuticals Inc. KALV$130.3 million last quarter
  2. Engene Holdings Inc. ENGN$32.5 million last quarter
  3. Tenax Therapeutics Inc. TENX$26.8 million last quarter
  4. Septerna Inc. SEPN$12.2 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Apogee Therapeutics Inc. APGE8,493,321$1.13 billion34.18%no change
Oruka Therapeutics Inc. ORKA4,148,428$394.8 million11.97%no change
Erasca Inc. ERAS17,891,812$327.8 million9.94%+1,509,000
Spyre Therapeutics Inc. SYRE2,985,448$265.0 million8.04%-700,000
Dianthus Therapeutics Inc. DNTH1,180,000$115.0 million3.49%no change
Ocular Therapeutix Inc. OCUL10,346,926$101.6 million3.08%no change
Galecto Inc. DMRA3,603,595$93.7 million2.84%no change
Savara Inc. SVRA14,745,943$90.8 million2.75%+1,005,568
Jade Biosciences Inc. JBIO3,220,364$71.6 million2.17%no change
Cogent Biosciences Inc. COGT1,642,166$63.6 million1.93%-357,834
Viridian Therapeutics Inc. VRDN3,257,917$59.8 million1.81%-624,792
Vor Biopharma Inc. VOR3,041,719$56.0 million1.70%no change
Dyne Therapeutics Inc. DYN2,173,913$48.3 million1.46%no change
Maze Therapeatics MAZE1,602,034$47.8 million1.45%no change
Relmada Therapeutics Inc. RLMD6,844,305$47.4 million1.44%+2,000,925
Oric Pharmaceuticals Inc. ORIC4,319,765$46.8 million1.42%no change
Crescent Biopharma Inc. CBIO2,133,576$38.4 million1.16%no change
Zura Bio Ltd ZURA6,434,990$38.0 million1.15%no change
Adlai Nortye Ltd ANL3,212,731$36.9 million1.12%no change
Enliven Therapeutics Inc. ELVN526,331$26.7 million0.81%-1,200,000
Cybin Inc. HELP3,851,654$25.5 million0.77%no change
Cullinan Therapeutics Inc. CGEM1,379,965$25.1 million0.76%no change
Century Therapeutics Inc. IPSC8,695,652$21.3 million0.65%no change
Artiva Biotherapeutics Inc. ARTV2,043,596$19.8 million0.60%+434,027
Cytomx Therapeutics Inc. CTMX4,982,124$18.7 million0.57%-5,000,000
Achieve Life Sciences Inc. ACHV2,751,032$18.0 million0.54%new
Parabilis Medicines Inc. Com PBLS625,000$17.1 million0.52%new
Surrozen Inc. SRZN632,931$16.4 million0.50%no change
Korro Bio Inc. KRRO1,009,500$13.3 million0.40%no change
Alto Neuroscience Inc. ANRO500,000$13.2 million0.40%no change
X4 Pharmaceuticals Inc. XFOR1,934,253$9.0 million0.27%+1,603,728
Research Alliance Corp Iii Ord Shs Cl A RACC300,000$3.2 million0.10%new
Inmed Pharmaceuticals Inc. INM32,685$50,6620.00%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 4 it sold out of are in the box above.